{"url_path":"/sec/maze/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1842295/0001193125-26-219430-index.html","accession_number":"0001193125-26-219430","cik":"0001842295","ticker":"MAZE","issuer_name":"Maze Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1842295/0001193125-26-219430-index.html","primary_entity_key":"0001842295","primary_entity_name":"Maze Therapeutics, Inc."},"word_count":153,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nRule 10b5-1 Trading Plans\n\nDuring the three months ended March 31, 2026, the following directors and/or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K:\n\n \n\nCharacter of Trading Arrangement\n\n \n\nAction\n\nDate of\n\nRule\n\nNon-Rule\n\nNature of\n\nAggregate Number\n\n \n\n \n\nDuration of Trading\n\nName and Title\n\nTaken\n\nAction\n\n10b5-1*\n\n10b5-1**\n\nTrading\n\nof Securities\n\n \n\n \n\nArrangement(1)\n\nJason Coloma, Chief Executive Officer and Director\n\nAdopted\n\nFebruary 6, 2026\n\nX\n\n \n\nSale\n\n \n\n414,012\n\n \n\n \n\n5/15/2026-5/15/2027\n\n*Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.\n\n**\"Non-Rule 10b5-1 trading arrangement\" as defined in Item 408(c) of Regulation S-K under the Exchange Act.\n\n1 The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed.\n\n \n\n78"}